Embryonic stem (ES) cells have the potential to differentiate into all cell types and are considered as a valuable source of cells for transplantation therapies. A critical issue, however, is the risk of teratoma formation after transplantation. The effect of the immune response on the tumorigenicity of transplanted cells is poorly understood. We have systematically compared the tumorigenicity of mouse ES cells and in vitro differentiated neuronal cells in various recipients. Subcutaneous injection of 1610 6 ES or differentiated cells into syngeneic or allogeneic immunodeficient mice resulted in teratomas in about 95% of the recipients. Both cell types did not give rise to tumors in immunocompetent allogeneic mice or xenogeneic rats. However, in 61% of cyclosporine A-treated rats teratomas developed after injection of differentiated cells. Undifferentiated ES cells did not give rise to tumors in these rats. ES cells turned out to be highly susceptible to killing by rat natural killer (NK) cells due to the expression of ligands of the activating NK receptor NKG2D on ES cells. These ligands were downregulated on differentiated cells. The activity of NK cells which is not suppressed by cyclosporine A might contribute to the prevention of teratomas after injection of ES cells but not after inoculation of differentiated cells. These findings clearly point to the importance of the immune response in this process. Interestingly, the differentiated cells must contain a tumorigenic cell population that is not present among ES cells and which might be resistant to NK cell-mediated killing. 
Introduction
Embryonic stem (ES) cells are a potential source of cells and tissues for transplantation in regenerative medicine. However, one of the critical issues is the risk of teratoma formation after transplantation of ES cells. It has been reported, e. g., that undifferentiated mouse ES cells can develop into functional dopaminergic neurons after intrastriatal transplantation in a rat model of Parkinson's disease but teratomas occurred in about 20% of the recipients which had been treated with cyclosporine A (CsA) for immunosuppression [1] . Transplantation of dopaminergic neurons differentiated in vitro from ES cells improved amphetamine-induced rotational behavior in the unilaterally 6-hydroxydopamine (6-OHDA)-lesioned rat model for Parkinson's disease [2] . These rats which were continuously treated with CsA did not develop teratomas [2] . Functional improvements without the development of teratomas have been observed after transplantation of neuronal cells differentiated from ES cells on PA6 feeder cells into the striata of 6-OHDA-lesioned rats which had not received any immunosuppressive treatment [3] . Despite the behavioral changes of the transplanted animals, the grafted cells remained in compact deposits surrounded by glia cells without functional integration into the host tissue [3] , which is postulated for an optimal long-term survival of grafts. When these in vitro differentiated neuronal cells were transplanted into CsA-treated recipients, tyrosine hydroxylase (TH)-positive neurites were present in the grafts suggesting a better integration of transplanted cells, however, now teratomas occurred in 2 of 15 animals [4] . In all these experiments a xenotransplantation was performed because rat ES cells are not readily available whereas the rat model allows for a reliable functional evaluation of grafts. The results might suggest that immunosuppression is required for functional integration of grafted cells but is associated with the risk of teratoma formation. Systematic comparative studies which address these questions are lacking. In one study a higher prevalence of teratomas was observed after intracerebral trans-plantation of ES cells in CsA-treated mice than in rats suggesting that the tumorigenesis of ES cells partially depends on the host [5] . Teratomas have been found also after injection of ES or in vitro differentiated cells into various other tissues including, e.g., liver [6] and myocardium [7] [8] [9] .
It has been proposed that teratoma formation can be prevented by in vitro pre-differentiation of ES cells [2] although conflicting results have been reported as well [4, 5] . In accordance with this hypothesis transplantation of ES cells into immunosuppressed allogeneic mice frequently leads to teratomas but in vitro predifferentiation can reduce the tumorigenicity of the grafts [10] . Sorting of cells expressing the neural precursor marker Sox1 before transplantation has been shown to further reduce the risk of teratoma formation [10, 11] . Furthermore, it has been reported that neuronal precursors can be enriched by inducing apoptosis in pluripotent stem cells using ceramide analogues so that teratoma formation is avoided [12] . These results are compatible with the common hypothesis that only undifferentiated stem cells can give rise to teratomas and that teratoma formation after injection of differentiated cells is caused by contamination of the grafts with undifferentiated cells.
In general, the effect of the immune response on the tumorigenicity of transplanted undifferentiated ES cells and in vitro differentiated cells is important but still poorly understood. Therefore, we systematically compared the tumorigenicity of mouse ES cells and in vitro differentiated neuronal cells after subcutaneous injection in immunocompetent and immunosuppressed syngeneic, allogeneic, and xenogeneic hosts.
Results

Tumorigenicity of ES cells and differentiated cells in syngeneic but not in allogeneic or xenogeneic hosts
We analyzed the tumorigenicity of ES cells (MPI-II) and ES cell-derived neuronal cells which were differentiated in vitro for 14 days in syngeneic, allogeneic, and xenogeneic hosts. Since we expected that ES cells would give rise to teratomas in syngeneic 129Sv mice, we determined the number of ES cells that were necessary to achieve tumor growth after subcutaneous injection in the majority of mice. Within 100 days tumors were observed in all mice which received at least 1610 6 ES cells (Table 1) . Therefore, the subsequent experiments were performed with a dose of 1610 6 cells. Syngeneic (129Sv), and allogeneic (C57BL/6 and C3H/HeN) mice as well as xenogeneic (LOU/c) rats were used as recipients. 129Sv and C57BL/6 mice share the major histocompatibility complex (MHC) haplotype H2 b . These mice differ therefore only in minor histocompatibility antigens, but not in the major histocompatibility antigens, i.e., the classical MHC class I and class II molecules. C3H/HeN mice carry the MHC haplotype H2 k and differ in major and minor histocompatibility antigens from 129Sv mice. Injection of 1610 6 ES cells or differentiated cells into syngeneic hosts resulted in about 95% of the animals in palpable tumors at the site of injection within 100 days post injection (Table 2) . In a few cases tumors that were palpable at least in 3 consecutive observations did not continue to grow and disappeared before day 100. Tumors grew early and rapidly in some animals, whereas small tumors remained stable for the whole observation time in others (Fig. 1) . We did not observe a statistically significant difference in the growth of tumors after injection of ES and differentiated cells, although a trend (p = 0.0673) towards a reduced growth of differentiated cells was observable (Fig. 1) . The growth of tumors was accelerated in male compared to female hosts (p,0.0001) after injection of the male ES cells (XY karyotype). We then determined the frequency of tumor growth after injection of various cell numbers of differentiated cells and observed a similar cell dose dependency as before for ES cells (Table 1) .
At the end of the experiments all animals underwent autopsy. No signs of regional or distant metastases were found. Histopathological evaluation identified all tumors as teratomas ( Fig. 2A, B) . Derivatives of the three germ layers were regularly observed during histopathological analysis of the tumors arising after injection of ES as well as in vitro differentiated cells. In agreement with the rapid growth of the tumors, the proliferation marker Ki67 was regularly detected by immunohistochemistry (Fig. 2F , Table 3 ). The pluripotency marker OCT3/4 (POU5F1) was not found to be expressed (Table 3) . T and B lymphocytes as well as macrophages were present in most teratomas (Fig 2C-E, Table 3 ) but obviously not able to prevent tumor growth in syngeneic mice. In several teratomas B cells appeared even to form lymph follicle-like ES cells and cells differentiated in vitro for 14 days were injected subcutaneously into the flank of syngeneic or allogeneic mice or xenogeneic rats (1610 6 cells in PBS/animal). Some recipients received an immunosuppressive treatment with CsA (10 mg/kg/day). The percentage and number of animals in which tumors were found during autopsy or in which tumors were palpable (at least during 3 consecutive observations) at the side of injection before day 100 after injection is indicated. in 1 mouse (7%) a tumor regression was observed before day 100. 4 in 2 mice (11%) a tumor regression was observed before day 100. 5 in 8 female mice (47%) a tumor regression was observed before day 100. 6 in 2 rats (11%) a tumor regression was observed before day 100. doi:10.1371/journal.pone.0002622.t002 structures (Fig. 2E) . The composition of teratomas with neuronal and glial cells was not different when tumors arising from ES cells and differentiated cells were compared (Table 4) .
Both cell types, ES and differentiated cells, did not give rise to tumors in xenogeneic LOU/c rats and in completely allogeneic C3H/HeN mice ( Table 2 ). Differences in minor histocompatibility antigens were sufficient to prevent progressive tumor growth because C57BL/6 recipients did also not develop tumors (Table 2) . Thus, the immune system appears to be able to prevent tumor growth after injection of ES and differentiated cells into allogeneic or xenogeneic hosts.
Low frequency of undifferentiated cells in the differentiation cultures
In syngeneic recipients both cell types led to tumors in similarly high frequency (,95%), indicating the presence of tumorigenic cells also after differentiation culture. However, in accordance with our previous data [3] less than 5% of the colonies in the differentiation cultures at day 14 contained cells positive for OCT3/4 and Ki67 (Fig. 3A-C) which might represent still undifferentiated ES cells. Ki67-positive but OCT3/4-negative cells were also found in these rare colonies (Fig. 3C) . Importantly, the vast majority of the cells in the differentiation cultures were III b-tubulin (Tuj1)-positive indicating a neuronal differentiation (Fig. 3D ). The few proliferating Ki67-positive cells were negative for neuronal markers (Fig. 3D) . In view of these characteristics of the in vitro differentiated cells, it was surprising that teratomas were equally frequent in syngeneic mice after injection of this heterogeneous but mainly neuronal cell population and a homogenous undifferentiated ES cell population.
Tumorigenicity of ES cells and differentiated cells in allogeneic immunodeficient hosts
To verify that the suppression of tumor growth in allogeneic hosts was indeed dependent on the immune system, the cells were injected into allogeneic SCID/beige mice which lack T and B lymphocytes as well as functional natural killer (NK) cells. In these recipients teratomas grew in similar frequency as in syngeneic hosts ( Table 2 ). No significant difference of tumor growth was observed after injection of ES and differentiated cells (Fig. 1B) . Interestingly, several teratomas of SCID/beige mice expressed OCT3/4 ( Fig. 2G ) in contrast to the tumors grown in syngeneic 129Sv mice (Table 3) , suggesting a removal of those cells in immunocompetent mice. The teratomas grown after injection of 6 ES cells (MPI-II) or in vitro differentiated cells (day 14 of differentiation culture) were injected subcutaneously at day 0 into syngeneic 129Sv mice (for the numbers of animals see Table 2 ). The tumor size was recorded every second day until day 100 using linear calipers. The growth of tumors in individual mice is shown. Tumor growth in female hosts is indicated by red and in male hosts by blue lines. (B) 1610 6 ES cells or in vitro differentiated cells were injected subcutaneously at day 0 into immunodeficient SCID/beige mice which are deficient for T, B, and functional NK cells. doi:10.1371/journal.pone.0002622.g001
ES cells and in vitro differentiated cells were stained for neuronal and glial markers (Fig. 4) and both cell types were found in a similar frequency (Table 4) .
PA6 feeder cells are not responsible for tumors observed after injection of differentiated cells
Differentiated cells were obtained by culturing MPI-II ES cells on a feeder layer of mitomycin-inactivated PA6 cells. We wanted to exclude that PA6 cells (derived from a C57BL/6 mouse) [13] could have contributed to the tumors. Therefore, we injected 1610 6 viable PA6 cells into groups of 6 to 8 C57BL/6, 129Sv, C3H/HeN, SCID/beige mice, and LOU/c rats. We did not observe any signs of tumor growth in these animals (data not shown). Thus, PA6 cells are not tumorigenic and do not contribute to the tumor growth after injection of differentiated cells.
Effect of immunosuppression on tumorigenicity of ES cells and differentiated cells in various hosts
After experimental transplantation of ES cells immunosuppression is frequently used to avoid rejection of the transplanted cells. Therefore, we determined the effect of immunosuppression on the tumorigenicity of the cells. In 129Sv mice treated with CsA (10 mg/kg/day) we observed teratomas in a similar frequency as in untreated animals ( Table 2 ). Interestingly, 8 of 10 female CsAtreated 129Sv mice injected with ES cells were able to reject the tumors within 100 days and in only one female a tumor was observed during autopsy. ES cells injected in parallel into male mice formed tumors in 6 of 6 cases ( Fig. 5A ). Thus, immunosuppression appeared to be associated with regression of ES cellderived tumors in female 129Sv recipients. Differentiated cells formed tumors in 4 of 6 male and 6 of 6 female CsA-treated 129Sv mice. In CsA-treated mice tumor growth appeared to be accelerated in male animals after injection of ES cells (p,0.0180) and in female mice after injection of differentiated cells (p,0.0001). Thus, the tumor growth might depend on a complex interaction between the injected cell type and sex of the host (p,0.0001). We did not observe a similar interaction of these factors in the untreated 129Sv mice (p = 0.8198). The progressively growing teratomas expressed Ki67 but no OCT3/4 (Table 3) . Interestingly, also the infiltration of the teratomas by T and B lymphocytes was not altered compared to the mice which did not receive CsA (Table 3) .
In CsA-treated allogeneic C57BL/6 and C3H/HeN mice small tumors (,10 mm 3 ) were detected in single cases (Table 2 ). However, injection of ES cells and differentiated cells did not lead to progressive tumor growth in CsA-treated allogeneic mice. Most surprisingly, injection of differentiated cells into CsA-treated LOU/c rats resulted in 11 of 18 cases in teratomas ( Table 2) . Tumor growth was observed in 9 of 9 male rats (Fig. 5B ). In two of One not rapidly growing tumor in each of these groups was negative for the marker.
2 not tested. 3 Teratomas grown in LOU/c rats were stained for infiltrating rat T and B cells as well as rat macrophages. doi:10.1371/journal.pone.0002622.t003 them an early tumor regression occurred. In addition, tumors were detected in 2 of 9 female rats within 100 days after inoculation (Fig. 5B) . It is important to notice that none of the CsA-treated rats (including 12 males and 13 females) developed tumors after injection of ES cells (Table 2) . Thus, the tumorigenicity of ES cells compared to differentiated cells was clearly reduced in CsA-treated rats (p,0.0001). After injection of differentiated cells the tumor growth was clearly dependent on the CsA treatment (p,0.0001) and on the sex of the host (p = 0.0127). The teratomas grown in the rats expressed Ki67 with exception of one non-progressive tumor. 5 of 9 teratomas expressed some OCT3/4 ( Fig. 2H) , as teratomas in immunodeficient mice did. However, it is not clear whether these OCT3/4-positive cells are ES cells from the grafts which survive when transplanted as contaminants of the tumorigenic differentiated cells or whether they represent another undefined cell population. All teratomas showed infiltration with rat T and B lymphocytes as well as rat macrophages (Table 3) . Rat NK cells were rarely found in these fully established tumors (data not shown). These experiments clearly demonstrate that tumorigenic cells are present among the in vitro differentiated cells which are not undifferentiated ES cells. Furthermore, it appears that the tumorigenicity of mouse ES cells in contrast to differentiated cells is controlled by a part of the rat's immune system which is not suppressed by CsA.
Susceptibility of ES cells to natural cytotoxic cells and expression of ligands for inhibitory and activating NK receptors
CsA is known to suppress the adaptive immune system by interfering with T cell signaling. We suspected that a natural cytotoxic activity that is not suppressed by CsA was able to prevent the growth of tumors derived from ES cells but not from differentiated cells. Therefore, we analyzed the susceptibility of ES cells and differentiated cells to killing by splenocytes derived from naïve LOU/c rats. ES cells in contrast to differentiated cells were killed readily in chromium release assays by splenocytes from LOU/c rats (Fig. 6A ). No differences in the cytotoxic activity between splenocytes of male and female rats were found. Lymphocytes derived from lymph nodes of the same animals did not show a cytotoxic activity against these targets (data not shown). Similar results were obtained when effector cells from other rat strains were used (see below Fig. 7 ). These results were in agreement with the assumption that NK cells, which are abundant in the spleen but rare in lymph nodes, can kill ES cells. We further isolated rat NK cells from spleens of naïve LOU/c rats by magnetic cell sorting of NKR-P1A-positive NK cells and used them directly without prior cytokine stimulation as effector cells in cytotoxicity assays against ES target cells. The purified NK cells were able to kill the ES cells and the typical NK target cell line YAC-1 in contrast to RMA cells which are known to be resistant to NK cells (Fig. 6B) . The cytotoxic activity of the NK cells could be inhibited by ethyleneglycol-bis(b-aminoethyl ester)-N,N,N9,N9-tetraacetic acid (EGTA, data not shown), indicating that the granule exocytosis pathway was used to kill the targets. The NK cell-depleted splenocyte fraction was not able to kill any of these target cell lines even at much higher effector target ratios (Fig. 6B) . Thus, the mouse ES cells were indeed susceptible to rat NK cells. We wondered why mouse NK cells were not able to suppress the teratoma growth in 129Sv mice after injection of ES cells. Interestingly, freshly isolated NK cells of naïve 129Sv mice completely failed to kill the ES cells. However, a short term culture in the presence of interleukin (IL)-2 was sufficient to activate them (Fig. 6C) . Stimulation of rat NK cells with IL-2 increased also their preexisting cytotoxic activity against ES cells (Fig. 6C) .
The cytotoxic activity of NK cells is known to be controlled by a set of inhibitory and activating NK receptors which are expressed on NK cells and interact with certain ligands on target cells. Ligands of inhibitory NK receptors are classical class I molecules, such as H2K and H2D. Ligands of activating NK receptors, such as NKG2D, include in the mouse the RAE-1 family as well as MULT-1 and H60 molecules. We determined the expression of classical MHC class I molecules (H2K b and H2D b ) and NKG2D ligands on ES and differentiated cells by flow cytometry (Fig. 6D) . MHC class I molecules were not detectable on ES cells but slightly up-regulated during differentiation. NKG2D ligands showed clearly the opposite expression pattern and were expressed only in ES cells (Fig. 6D) . The RAE-1 proteins were the NKG2D ligands expressed on the ES cells (Fig. 6E) . NKG2D ligands on ES cells were most likely responsible for the susceptibility of these cells to rat NK cells since the NK cell-mediated killing could be blocked by a soluble NKG2D protein (Fig. 6F) . Similarly, the killing by activated mouse NK cells could be inhibited by the soluble NKG2D protein and also by inhibitory antibodies against RAE-1 molecules (Fig. 6G ).
Cellular cytotoxicity against ES cells in rats after intracerebral grafting of differentiated cells
Rats are widely used as hosts to evaluate functional properties of cells which are differentiated in vitro from mouse ES cells [1, 2] . The differentiated cells analyzed here were evaluated previously for their therapeutic potential in a rat model of Parkinson's disease [3, 4] . In this model 10 5 differentiated cells were transplanted into the striata of unilaterally 6-OHDA-lesioned rats. We now analyzed the cytotoxic activity of effector cells from transplanted rats 6 weeks after intrastriatal grafting. Rats from two inbred rat strains (DA and LEW.1N) and one outbred strain (Wistar) were used as recipients in these experiments. The animals did not receive any immunosuppressive therapy after transplantation. No teratomas were found in the brains of these animals (data not shown), confirming our previous observations [3] .
Freshly isolated splenocytes from 4 of 5 grafted and two untreated control DA rats killed ES cells in chromium release assays at least to certain extend (Fig. 7A) . A detectable killing is defined here as a mean specific lysis of more than 5% at least for the two highest effector target ratios. Differentiated cells were moderately killed only by cells from one grafted (no. 113) and one control (co 1) DA rat (Fig. 7B) . Splenocytes obtained from all grafted and control LEW.1N rats killed ES cells (Fig. 7C) . However, a low cytotoxic activity against differentiated cells was observed with splenocytes from only one grafted (no 120) and one control (co 2) LEW.1N rat (Fig. 7D) . The cytotoxic activity of splenocytes from Wistar rats against ES cells appeared to be reduced compared to the other strains (Fig. 7E) . Splenocytes from all animals failed to kill differentiated cells (Fig. 7F) . However, a short term culture with IL-2 was usually sufficient to increase their cytotoxic activity against ES cells (Fig. 7G) . Thus, a natural cytotoxic activity against mouse ES cells exists not only in LOU/c rats but also in other rat strains such as DA and LEW.1N.
NK cells appear to contribute to the rejection of ES cells in vivo but further immune mechanisms might be involved
The presence of NK cells with cytotoxic activity against ES cells in naïve and transplanted rats suggest that they might influence the outcome of the transplantation. However, in syngeneic 129Sv 6 ES cells or in vitro differentiated cells were injected subcutaneously at day 0 into syngeneic 129Sv mice (for the numbers of animals see Table 2 ) which were treated daily with CsA (10 mg/kg body weight). The tumor size was recorded every second day until day 100 using linear calipers. The growth of tumors in individual mice is shown. Tumor growth in female hosts is indicated by red lines and male hosts by blue lines. (B) 1610 6 cells differentiated in vitro for 14 days were injected subcutaneously into LOU/c rats (n = 18) which were treated daily with CsA (10 mg/kg body weight). The tumor size was recorded every second day until day 100 using linear calipers. The growth of tumors in individual rats is shown. Tumor growth in female hosts is indicated by red and in male hosts by blue lines. One tumor in a female rat was not progressive and remained very small until the end of the experiment. In two male rats a tumor regression occurred. doi:10.1371/journal.pone.0002622.g005 (Fig. 8A) . Thus, the injection of ES cells alone might not be sufficient to activate the NK cells in mice. Therefore, we tried to inhibit the preexisting NK cell activity in rats. Unfortunately, in rats a genetic model of NK cell deficiency is not available. It has been shown that injection of high doses of monoclonal antibodies against the NKR-P1A molecule can transiently inhibit NK cell cytotoxicity in vivo [14] . We speculated that a transient inhibition of NK cells could be sufficient to allow for a differentiation of injected ES cells in vivo into a pluripotent and NK cell resistant cell population which could then give rise to teratomas. The treatment scheme and the efficiency of NK cell depletion are shown in Fig. 8B and 8C. In 2 of 8 male LOU rats small tumors were found at the injection site but none of the 6 control rats treated with an isotype control showed a tumor (Fig. 8D) . Taking into account the limited efficiency of a transient NK cell inhibition, these data suggest that NK cells could contribute to the control of teratoma growth but likely further immune mechanisms are involved in the rejection of mouse ES cells in CsA-treated rats.
Discussion
It is well known that mouse [8, 10, [15] [16] [17] [18] and human ES cells [19, 20] can give rise to teratomas when injected into immunodeficient hosts. The ability of cells to form teratomas in such recipients can even be used as an in vivo test for their pluripotency [21] . Mouse ES cells can also form teratomas in syngeneic [9, 22, 23] and allogeneic hosts [8, 9, 17] and even in xenogeneic recipients such as rats [1, 5] . The frequency of tumors varied in these studies. This is probably depending on the ES cell lines used [24] , the degree of histoincompatibility between transplanted cells and recipients, the immunosuppressive treatment of the recipients, and the site of transplantation [24, 25] , especially when it is an immune-privileged organ. The situation is even more complex after transplantation of in vitro differentiated cells. Again teratomas have been observed in some studies in syngeneic [9, 22] , allogeneic [6] and xenogeneic hosts [4, 5] . However, the results might have been also strongly influenced by the differentiation protocols and selection strategies [9] [10] [11] [12] .
We have used one ES cell line (MPI-II) and one differentiation protocol [3, 26] that after 14 days of culture results in about 95% Tuj1-positive neuronal cells and about 30% TH-positive dopaminergic cells [3, 26] . The same differentiation protocol has also been successfully used for the dopaminergic differentiation of human [27] [28] [29] and non-human primate ES cells [30, 31] . These differentiated mouse cells have been shown previously to improve the amphetamine-induced rotational behavior in unilaterally 6-OHDA-lesioned and not immunosuppressed rats after intrastriatal transplantation [3] . However, these cells gave rise to teratomas in 2 of 15 CsA-treated animals [4] .
Subcutaneous injection of either 1610 6 ES cells or differentiated cells led to teratoma growth in about 95% of the syngeneic 129Sv recipients. It was surprising that neither frequency nor growth of the tumors derived from differentiated cells were significantly reduced. We have shown in a pilot experiment that a 10-fold reduction of the number of ES cells reduced the tumor frequency. The proportion of undifferentiated cells which still might have been present after in vitro differentiation was less than 10% [3] . Thus, it appears to be questionable whether only completely undifferentiated ES cells can contribute to the teratoma formation. In allogeneic mice and xenogeneic rats no tumor growth was observed. A mismatch in minor histocompatibility antigens was sufficient to suppress the tumorigenesis as shown in C57BL/6 recipients which share the MHC haplotype H2 b with 129Sv mice. Since both ES and differentiated cells formed teratomas in allogeneic immunodeficient SCID/beige mice the immune response was indeed responsible for the suppression of tumors after allogeneic transplantation.
Immunosuppression with CsA did not augment the tumorigenicity of the cells in allogeneic mice. However, this was different for xenogeneic rat recipients. ES cells were not able to form teratomas in CsA-treated rats but in vitro differentiated cells lead to progressive tumor growth in about 50% of the animals. This finding clearly indicates that differentiated cells must contain a tumorigeneic cell population that is different from the ES cells. These cells might be even more tumorigeneic than ES cells because this subpopulation of cells present in differentiation cultures gave rise to teratomas in a similar frequency as a homogenous ES cell population. The CsAtreatment which suppresses the activation of T lymphocytes does apparently not impair the rejection of ES cells. The rejection of the novel tumorigenic cell population among differentiated cells in non CsA-treated hosts must be mediated by a part of the immune system which is affected by CsA such as cytotoxic T lymphocytes (CTL). These observations challenge the common view that only completely undifferentiated ES cells can give rise to teratomas. Some cells which arise in the differentiation culture obviously retain pluripotency. The molecular characteristics of these cells are unknown. They might represent a physiological differentiation step or, alternatively, a pathological miss-differentiation might occur in some cells during the in vitro differentiation culture. We assume that a pluripotent cell population exists in the differentiation culture which is an intermediate between ES cells and neuronal cells. These cells must be different from neural rosette cells (R-NSC) because the histopathological evaluation of the tumors from CsA-treated rats indicated undoubtedly the growth of teratomas after injection of in vitro differentiated cells and not a ''rosette overgrowth'' that has been described recently after grafting of ES cell-derived R-NSCs [32] .
Interestingly, the teratoma growth appeared to be accelerated in male immunocompetent syngeneic mice and xenogeneic rats. Therefore, the teratoma growth might be supported by male hormones. The risk of teratoma formation appears to be influenced by a complex interaction between sex and immune status of the recipients that needs further exploration. Therefore, it will be of interest to determine in further experiments the tumorigenicity of female ES cells in female as well as in male recipients.
Rather little is known about the immune response that occurs after transplantation of ES cells or cells differentiated from ES cells [33] [34] [35] . We speculated that NK cells might be involved in the mean of specific lysis of the target cells by rat NK cells at an effector to target ratio of 20:1 was determined as described above and adjusted to 100%. For inhibition of lysis a soluble mouse NKG2D protein was added to the test at a concentration of 3 mg/ml. The relative lysis of the target cells exposed to NKG2D was calculated. (G) The mean inhibition+SD of specific lysis of ES cells by soluble mouse NKG2D and various inhibitory antibodies against NKG2D ligands is shown. The mean of specific lysis of the target cells by IL-2 activated mouse NK cells at an effector to target ratio of 10:1 was determined as described above and adjusted to 100%. For inhibition of lysis a soluble mouse NKG2D protein or the indicated mAbs were added to the test at a concentration of 3 mg/ml. The relative lysis of the target cells exposed to NKG2D or the mAbs was calculated. doi:10.1371/journal.pone.0002622.g006 rejection of ES cells in the CsA-treated rats, because their cytotoxic activity is not generally impaired by CsA, although in humans some effects of CsA on NK subpopulations have been described recently [36] . Furthermore, mouse as well as human ES cells might be a target for NK cells because they express no or low amounts of MHC class I molecules [8, 17, 37, 38] which serve as ligands for inhibitory NK receptors [39] . The expression of MHC class I molecules has been described to increase during in vitro differentiation of ES cells [40, 41] . Cells which express no MHC class I molecules might fail to inhibit the cytotoxic NK cell activity [42] . Human NK cells have been shown to kill human ES cell lines which expressed small amounts of ligands for the activating NK receptor NKp44 [37] . On the other hand it has been reported that mouse NK cells are not important for the rejection of human ES cells in vivo [19] . Alternatively, the complement system has been shown to contribute to the control of teratoma growth after transplantation of ES cells [18] .
We found a high cytotoxic activity of splenocytes derived from naïve rats against the ES cells and a low activity against differentiated cells. Flow cytometry did not indicate the presence of MHC class I molecules (H2K and H2D) on these cells and the differentiation only moderately increased H2K expression. Interestingly, the ES cells expressed ligands for the activating NK receptor NKG2D. Recognition of these ligands by NKG2D on NK cells is known to trigger cytotoxicity [43] and the killing of the ES cells by rat NK cells as well as IL-2 activated mouse NK cells was indeed dependent on NKG2D. NKG2D ligands were down-regulated during differentiation culture and this finding explains the reduced susceptibility of these targets to natural cytotoxic cells much better than the observed moderate upregulation of H2K molecules. These results could suggest that ES cells were rapidly destroyed in immunocompetent as well as in CsA-treated rat recipients by NK cells before teratomas were formed. Differentiated cells which are NK cell resistant but still tumorigenic could have given rise to teratomas in CsA-treated rats which fail to reject these cells due to the impaired adaptive immune system. Although an antibody-mediated NK cell depletion is not as effective as a genetic NK cell deficiency, our respective experiment resulted in small teratomas in a subgroup of rats, suggesting that NK cells might be involved in the rejection of ES cells in CsA-treated rats. However, in addition NK cells, likely further immune mechanisms contribute to the removal of ES cells. The unimpaired teratoma growth in SCID mice could even argue that mouse NK cells are not important at all for the rejection of ES cells [19] . However, one should notice that mouse NK cells had to be activated by IL-2 to become able to kill the ES cells in vitro. Therefore, the effect of mouse and rat NK cells on teratoma growth might depend on the degree of an inflammatory response after transplantation which can lead to NK cell activation. NKG2D ligands appear to represent new markers for ES cells. Due to their expression at the cell surface they are potentially useful for sorting of ES and differentiated cells. NKG2D ligands include in the mouse RAE-1, H60, and MULT-1 [43] . These ligands are not expressed normally but they can become induced in response to stress, such as heat shock [44] , virus infection [45] , or genotoxic stress [46] . They might signal the presence of potentially dangerous cells to the immune system [47] . The expression of these ligands in tumor cells is known to contribute to the tumor surveillance by the immune system [43] . The NKG2D ligands found to be expressed on the ES cells belong mainly to the RAE-1 family. This finding is in accordance with one previous study, however, these authors reported that RAE-1 molecules on mouse ES cells do not confer susceptibility to lysis by NK cells [48] . It remains to be elucidated whether the expression of these ligands on ES cells has a physiological function. NKG2D ligands could allow, e. g., for the removal of displaced and potentially dangerous pluripotent cells by the immune system.
Recently it has been reported that mouse ES cells are resistant to antigen-specific CTL due to the expression of serpin-6 which is an endogenous inhibitor of granzyme B [40] . However, the MPI-II cells analyzed here were susceptible to granule exocytosismediated killing by rat NK cells and also by peptide-specific mouse CTL (own unpublished data). Thus, ES cells are not generally protected against cellular cytotoxicity. Human ES cell lines were also reported to be susceptible to human CTL [49] . It has to be investigated further whether ES cell lines vary in their susceptibility against the cytotoxic mechanisms of the immune system.
Much research efforts are currently directed towards the establishment of pluripotent cells from individuals which might be subsequently used for syngeneic transplantations before or after in vitro differentiation. These strategies might be associated with an increased risk of teratoma formation. Thus, it might be worthwhile to thoroughly evaluate whether allogeneic stem cells can be used as an effective and safe new therapeutic tool in regenerative medicine.
Materials and Methods
ES cell culture and neuronal differentiation culture
Undifferentiated mouse ES cells (MPI-II, 129Sv strain, XY karyotype) were expanded on gelatin-coated cell culture dishes in Glasgow minimal essential medium (GIBCO-Invitrogen, Karlsruhe, Germany) containing 1% fetal calf serum (FCS), 10% knockout replacement, 2 mM glutamine, 0.1 non essential amino acids, 1 mM sodium pyruvate, 0.1 mM 2-mercaptoethanol, 2000 U/ml leukemia inhibitory factor (GIBCO). The neuronal differentiation was induced in a culture on mitomycin Cinactivated PA6 feeder cells as described [3, 26] . On day 14 of the culture cells were used for experiments and are named throughout this study as ''differentiated cells''.
Culture of cell lines
The mouse lymphoma cell lines YAC-1 (H2 a ) and RMA (H2 b ) were maintained in NaHCO 3 -buffered Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS (Biochrom, Berlin, Germany), 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin, and 100 mg/ml streptomycin. PA6 feeder cells were cultured in the same medium on gelatin-coated cell culture plates.
Animal experiments
Animals were bred in the central animal facility of the Medical Faculty of the University of Göttingen. Animal experiments had been approved by the local government. Rats (DA, LEW.1N, LOU/ c, Wistar) and immunocompetent mice (129Sv, C3H/HeN, C57BL/6) were conventionally housed whereas severe combined immunodeficient SCID/beige (C.B-17/IcrHsd-scid-bg) and SCID (C.B-17/Ztm-scid) mice were kept under pathogen-free conditions. A subgroup of animals received daily intraperitoneal injections of CsA (10 mg/kg, Sandimmune, Novatis Pharma, Nürnberg) starting two days before grafting. For the depletion of NK cells, some rats received in addition to CsA intraperitoneal injections of the monoclonal antibody (mAb) anti-NKR-P1A (clone 10/78, mouse IgG 1 , BD Biosciences, Heidelberg, Germany) or the respective isotype control (clone PPV-06, mouse IgG 1 , Exbio, Prague, Czech Republic). The anti-NKR-P1A mAb (clone 10/78) is directed against the same epitope as the mAb (clone 3.2.3) which has been used previously to deplete NK cells in rats [14] . One mg of the respective antibodies were given one day before the injection of ES cells followed by 0.5 mg at day 4 after cell transplantation. Blood samples were taken before starting these experiments, at day 0 and 4 days after cell transplantation, and at autopsy (day 92) in order to determine the proportion of NK cells in the blood by flow cytometry. For the analysis of subcutaneous tumor growth ES or differentiated cells were injected in 100 ml phosphate-buffered saline (PBS) into the flank of the animals. Tumor growth was monitored every second day by palpation and size was recorded using linear calipers. The tumor volume was calculated by the formula V = pabc/2, where a, b, c are the orthogonal diameters. Animals were sacrificed before day 100 when a tumor volume of 1 cm 3 in mice and 5 cm 3 in rats was reached, when a weight loss of more than 10% occurred, or when any behavioral signs of pain or suffering were observable. Autopsies of all animals were performed. Tumor tissue was immediately frozen in liquid nitrogen or placed in phosphate-buffered 4% formalin for 16 h and then embedded in paraffin. Spleens and lymph nodes were removed for subsequent immunological analyses. The transplantation of cells into the striatum of unilaterally 6-OHDA-lesioned rats was performed as previously described [3] . These animals were sacrificed 6 weeks after transplantation.
Histology, immunohistochemistry, and immunofluorescence
Tissue sections (2.5 mm) were stained with hematoxylin and eosin (HE) for histological examinations. For immunohistochemistry, intrinsic peroxidase activity was blocked by incubation with 5% H 2 O 2 in PBS for 20 minutes after deparaffinization. Non-specific antibody binding was inhibited with 10% FCS in PBS for 25 minutes. Microwave pre-treatment for antigen retrieval was regularly performed with exception of the sections for the NeuN and glial fibrillary acidic protein (GFAP) stainings. Immunohistochemical staining was performed with an avidin-biotin technique. The primary mAbs for immunohistochemistry were anti-NeuN 
Flow cytometry
Flow cytometry was performed on a FACScan TM flow cytometer (BD Biosciences) using CellQuest TM software. The cell surface expression of MHC class I molecules was analyzed using locus and haplotype-specific mAbs anti-H2K b (clone CTKb, mouse IgG 2a , phycoerythrin (PE)-conjugated, Caltag Laboratories, Hamburg, Germany), and anti-H2D b (clone CTDb, mouse IgG 2a , PE-conjugated, Caltag). A recombinant mouse NKG2D-Fc chimeric protein (139-NK; R&D Systems) was used to detect cell surface expression of NKG2D ligands. A polyclonal fluorescein isothiocyanate (FITC)-conjugated goat anti-human IgG (109-095-098; Jackson Laboratories, Dianova, Hamburg, Germany) served as secondary reagent. The following mAbs were used to detect specific NKG2D ligands: anti-RAE-1 (pan-specific, clone 186107, rat IgG2a, R&D Systems), anti-H60 (clone 205326, rat IgG2a, R&D Systems), and anti-MULT-1 (clone 237104, rat IgG2a, R&D Systems). A polyclonal FITC-conjugated goat anti-rat IgG (212-095-082; Jackson Laboratories, Dianova) served as secondary reagent. The purity of rat NK cells separated by magnetic cell sorting (MACS) and the proportion of NK cells in the blood of rats were assessed using an anti-NKR-P1A mAb (clone 10/78, mouse IgG1, PE-conjugated, Caltag). Erythrocytes in blood samples were lysed before analysis using a FACS lysing solution (BD Biosciences) according to the manufactures instructions. The purity of MACSseparated mouse NK cells was assessed using the pan-NK cell marker CD49b (clone DX5, rat IgM, PE-conjugated, Caltag). Isotype controls were purchased from Caltag.
Effector cells and 51
Chromium release assays
Lymphocytes were obtained from spleens or lymph nodes using a Tenbroeck homogenizer. Erythrocytes were removed from splenocytes by density gradient centrifugation on Biocoll (Biochrom). The cells were used either directly as cytotoxic effector cells or cultured for 4 days in DMEM supplemented with 10% FCS, 50 mM 2-mercaptoethanol, and 1000 U/ml IL-2 (Chiron, Amsterdam, Netherlands) to obtain lymphokine-activated killer (LAK) cells. Rat NK cells were isolated by MACS using a biotinconjugated anti-NKR-P1A Ab (clone 10/78, mouse IgG 1 , BD Biosciences) and paramagnetic anti-biotin micro beads (130-090-485, Miltenyi Biotec, Bergisch-Gladbach, Germany) according to the manufactures instructions. Mouse NK cells were isolated using a negative selection kit (NK cell isolation Kit mouse, 130-090-864; Miltenyi Biotec). The kit contains a cocktail of antibodies against CD4, CD5, CD8a, CD19, Ly-6G, and Ter-119 and depletes the non-NK cells. To activate NK cells in vitro they were cultured in DMEM supplemented with 10% FCS, 50 mM 2-mercaptoethanol, and 1000 U/ml IL-2. 51 Chromium release assays were performed as previously described [50, 51] . A recombinant mouse NKG2D-Fc chimeric protein (139-NK) purchased from R&D Systems (Wiesbaden, Germany) was used to inhibit the part of lysis of target cells which was dependent on the expression of NKG2D ligands. Similarly, antibodies which block the binding of NKG2D to RAE1b (MAB17581, clone 199205, rat IgG 2a , R&D Systems), RAE-1a and RAE-1c (MAB 1758, clone 199215, ratIgG 2a , R&D Systems), and H60 (clone 205326, rat IgG 2a , R&D Systems) were used for blocking experiments. A rat IgG 2a isotype control was purchased from Caltag.
Statistics
A nonparametric ANOVA-like method for longitudinal data based on ranks was used [52] to compare the tumor growth in different experimental groups. Due to numerical issues we compared tumor growth curves longitudinally using the following time points: 10, 20, 30, 40, and 50 days post injection.
